Immune-checkpoint inhibitor resistance in patients with cancer
Open Access
- 20 May 2025
- journal article
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 5, 1003196
Abstract
The introduction of immune checkpoint inhibitors (ICIs) has transformed the landscape of oncology, offering significant improvements in patient survival and achieving remarkable long-term outcomes. Despite these advances, the therapeutic benefits of ICIs are not universal, and existing biomarkers often fall short in accurately predicting patient responses. A comprehensive understanding of the mechanisms underlying resistance to ICIs is essential for the development of strategies to mitigate these challenges and enhance therapeutic efficacy. This review provides a detailed exploration of the resistance mechanisms associated with ICIs, focusing on the role of the tumor microenvironment and intrinsic tumor cell alterations in mediating both primary and secondary resistance. Furthermore, it evaluates emerging strategies to overcome resistance, including combination therapies and innovative therapeutic approaches. By dissecting the molecular and immunological pathways implicated in ICI resistance, this review aims to highlight novel predictive and prognostic biomarkers and outline optimized therapeutic strategies to maximize the clinical impact of ICIs in cancer management.Keywords
This publication has 299 references indexed in Scilit:
- Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trialCancer Medicine, 2024
- Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast CancerJAMA Oncology, 2019
- Extracellular matrix (ECM) stiffness and degradation as cancer driversJournal of Cellular Biochemistry, 2018
- Interferon gamma in cancer immunotherapyCancer Medicine, 2018
- Expression of scavenger receptor MARCO defines a targetable tumor‐associated macrophage subset in non‐small cell lung cancerInternational Journal of Cancer, 2018
- PD‐L1 co‐stimulation contributes to ligand‐induced T cell receptor down‐modulation on CD8+ T cellsEMBO Molecular Medicine, 2011
- Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cellsEuropean Journal of Immunology, 2005
- Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3)European Journal of Immunology, 2002
- CTLA4 ligation attenuates AP-1, NFAT and NF-κB activity in activated T cellsEuropean Journal of Immunology, 1999
- Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.The EMBO Journal, 1992